Gastrointestinal
FDA Officials Reject NDA, in Current Form, for Gastroparesis Treatment
FDA Officials Reject NDA, in Current Form, for Gastroparesis Treatment
If approved, Gimoti would be the first non-oral drug treatment for symptoms associated with acute and recurrent diabetic gastroparesis in adult women and would represent the first significant advancement in the treatment of gastroparesis in 40 years.
Read More >>
FDA Approves TAS-102 for Treating Adults With Gastric/GEJ Cancer
FDA OKs Rifamycin for Travelers' Diarrhea Caused by Noninvasive E coli
Opioid-Induced Constipation
FDA Approves Eravacycline for Adults With Complicated Intra-Abdominal Infections
FDA OKs Eravacycline for Complicated Intra-Abdominal Infections
5 Things Pharmacists Should Know About the Recent Cyclospora Outbreak
Irritable Bowel Syndrome: Newer Drugs Provide Relief
View more articles >>
Clinical Trials
Physiological Predictors of Clinical Outcomes After Anti-reflux Surgery
Correlations Between Wireless pH Monitoring and Variation in Reflux Symptom Questionnaire, 7 Day Recall
Extraesophageal Reflux - Feasibility of Measurement of Pepsin in Saliva as a Diagnostic Option
Fermented Soy and Heartburn Symptom Relief
A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer
Multimedia: Videos
What Lifestyle Interventions Can Pharmacists Recommend to Avoid Stomach Upset?
What Lifestyle Interventions Can Pharmacists Recommend to Avoid Stomach Upset?
How Should Pharmacists Counsel Patients on PPI Use for Heartburn?
How Should Pharmacists Counsel Patients on PPI Use for Heartburn?
How New Agents are Helping Address Clostridium Difficile-Associated Diarrhea Concerns
How New Agents are Helping Address Clostridium Difficile-Associated Diarrhea Concerns
Acid Reflux: More Than a Nuisance
Acid Reflux: More Than a Nuisance